# GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.

> **NCT04942756** · NA · UNKNOWN · sponsor: **Antea Foundation** · enrollment: 118 (estimated)

## Conditions studied

- Palliative Care
- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Type 1
- Diabetes
- Cancer
- Terminal Cancer
- Terminal Illness
- End Stage Cancer
- Advanced Cancer

## Interventions

- **DEVICE:** Continuous Glucose Monitoring
- **DEVICE:** Standard Care

## Key facts

- **NCT ID:** NCT04942756
- **Lead sponsor:** Antea Foundation
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-30
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2021-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04942756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04942756, "GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04942756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*